Published in Cancer Gene Ther on February 01, 2005
Strategies to Optimize Adult Stem Cell Therapy for Tissue Regeneration. Int J Mol Sci (2016) 0.87
Suppression of human colon tumor growth by adenoviral vector-mediated NK4 expression in an athymic mouse model. World J Gastroenterol (2007) 0.78
NK4, an HGF antagonist, prevents hematogenous pulmonary metastasis by inhibiting adhesion of CT26 cells to endothelial cells. Clin Exp Metastasis (2009) 0.77
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med (2010) 27.12
Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol (2006) 6.55
Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2005) 5.83
Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell (2002) 5.69
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol (2013) 4.30
Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res (2008) 4.30
First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol (2009) 4.05
Severe acute interstitial pneumonia and gefitinib. Lancet (2003) 3.94
Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell (2012) 3.90
Radixin deficiency causes conjugated hyperbilirubinemia with loss of Mrp2 from bile canalicular membranes. Nat Genet (2002) 3.06
Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Res (2004) 2.42
Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2004) 2.35
Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med (2008) 2.29
Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res (2009) 2.27
Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth. J Clin Invest (2005) 2.20
A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol (2008) 2.01
Mutations in the SLC34A2 gene are associated with pulmonary alveolar microlithiasis. Am J Respir Crit Care Med (2006) 1.98
Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection. J Virol (2005) 1.97
Hepatocyte growth factor stimulates proliferation of respiratory epithelial cells during postpneumonectomy compensatory lung growth in mice. Am J Respir Cell Mol Biol (2002) 1.91
Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol (2008) 1.88
Hepatocyte growth factor twenty years on: Much more than a growth factor. J Gastroenterol Hepatol (2011) 1.87
Therapeutic effect of transplanting HGF-treated bone marrow mesenchymal cells into CCl4-injured rats. J Hepatol (2005) 1.86
Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer (2010) 1.79
Arkadia amplifies TGF-beta superfamily signalling through degradation of Smad7. EMBO J (2003) 1.68
Expression of urocortin and corticotropin-releasing factor receptor subtypes in the human heart. J Clin Endocrinol Metab (2002) 1.66
Gene transfer of hepatocyte growth factor gene improves learning and memory in the chronic stage of cerebral infarction. Hypertension (2006) 1.54
Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res (2009) 1.52
Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. Clin Cancer Res (2009) 1.51
Two distinct pathways of tumorigenesis of adenocarcinomas of the esophagogastric junction, related or unrelated to intestinal metaplasia. Pathol Int (2007) 1.50
Circulating long non-coding RNAs in plasma of patients with gastric cancer. Anticancer Res (2013) 1.49
A novel role of hepatocyte growth factor as an immune regulator through suppressing dendritic cell function. J Immunol (2005) 1.49
Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. Int J Cancer (2006) 1.48
Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. Cancer Res (2002) 1.47
Subtotal gastrectomy for cancer located in the greater curvature of the middle stomach with prevention of the left gastric artery. Am J Surg (2002) 1.46
Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit Rev Oncol Hematol (2005) 1.45
Successful use of ketamine for intractable burning pain of HTLV-1-associated myelopathy. J Pain Symptom Manage (2005) 1.42
Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. Clin Cancer Res (2012) 1.42
Differential diagnosis of gallbladder cancer using positron emission tomography with fluorine-18-labeled fluoro-deoxyglucose (FDG-PET). J Surg Oncol (2003) 1.39
Proinflammatory cytokine IL-1 beta promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumor-stromal interaction. J Immunol (2002) 1.39
Oral administration of a novel long-acting prostacyclin agonist with thromboxane synthase inhibitory activity for pulmonary arterial hypertension. Circ J (2013) 1.39
Paracrine factors of multipotent stromal cells ameliorate lung injury in an elastase-induced emphysema model. Mol Ther (2010) 1.39
Targeted delivery of CX3CL1 to multiple lung tumors by mesenchymal stem cells. Stem Cells (2007) 1.35
LIMK1 regulates Golgi dynamics, traffic of Golgi-derived vesicles, and process extension in primary cultured neurons. Mol Biol Cell (2004) 1.35
Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis. Am J Respir Crit Care Med (2010) 1.34
First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. J Thorac Oncol (2012) 1.33
Tryptophan 2,3-dioxygenase is a key modulator of physiological neurogenesis and anxiety-related behavior in mice. Mol Brain (2009) 1.32
Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappa B transcription factors. J Antimicrob Chemother (2002) 1.31
[Obstruction of an reinforced endotracheal tube due to dissection of internal tube wall during total intravenous anesthesia]. Masui (2003) 1.31
Increased susceptibility to LPS-induced endotoxin shock in secretory leukoprotease inhibitor (SLPI)-deficient mice. J Exp Med (2003) 1.30
Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors. FASEB J (2003) 1.29
Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. Clin Cancer Res (2011) 1.28
Hepatocyte growth factor: from diagnosis to clinical applications. Clin Chim Acta (2003) 1.25
Chemoenzymatic synthesis and application of glycopolymers containing multivalent sialyloligosaccharides with a poly(L-glutamic acid) backbone for inhibition of infection by influenza viruses. Glycobiology (2002) 1.24
Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res (2002) 1.22
OX40 ligand expressed by DCs costimulates NKT and CD4+ Th cell antitumor immunity in mice. J Clin Invest (2007) 1.21
NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci (2003) 1.21
HGF reduces advancing lung fibrosis in mice: a potential role for MMP-dependent myofibroblast apoptosis. FASEB J (2005) 1.19
Comparison of effects in randomized controlled trials with observational studies in digestive surgery. Ann Surg (2006) 1.19
In vivo evidence of angiogenesis induced by transcription factor Ets-1: Ets-1 is located upstream of angiogenesis cascade. Circulation (2004) 1.19
Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1. J Bone Miner Res (2004) 1.19
Interleukin (IL)-21 and IL-15 genetic transfer synergistically augments therapeutic antitumor immunity and promotes regression of metastatic lymphoma. Mol Ther (2003) 1.18
Identification of tumor-initiating cells in a highly aggressive brain tumor using promoter activity of nucleostemin. Proc Natl Acad Sci U S A (2009) 1.17
Growth inhibition and apoptosis in liver myofibroblasts promoted by hepatocyte growth factor leads to resolution from liver cirrhosis. Am J Pathol (2005) 1.17
Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Mol Cancer Ther (2012) 1.17
Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25+Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A (2010) 1.16
Three-step esophagojejunal anastomosis with atraumatic anvil insertion technique after laparoscopic total gastrectomy. J Gastrointest Surg (2011) 1.16
Instabilotyping reveals unique mutational spectra in microsatellite-unstable gastric cancers. Cancer Res (2002) 1.16
Targeting apoptotic tumor cells to Fc gamma R provides efficient and versatile vaccination against tumors by dendritic cells. J Immunol (2003) 1.16
Outcome of surgical treatment for patients with scirrhous carcinoma of the stomach. Am J Surg (2004) 1.16
Mechanisms and significance of bifunctional NK4 in cancer treatment. Biochem Biophys Res Commun (2005) 1.15
Intranasal HGF administration ameliorates the physiologic and morphologic changes in lung emphysema. Mol Ther (2008) 1.15
Hepatocyte growth factor induces angiogenesis in injured lungs through mobilizing endothelial progenitor cells. Biochem Biophys Res Commun (2004) 1.15
Overexpression of HGF retards disease progression and prolongs life span in a transgenic mouse model of ALS. J Neurosci (2002) 1.14
Hepatocyte growth factor ameliorates the progression of experimental autoimmune myocarditis: a potential role for induction of T helper 2 cytokines. Circ Res (2005) 1.12
Mannose-binding lectin gene polymorphism is a modulating factor in repeated respiratory infections. Chest (2004) 1.12
Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer. Clin Cancer Res (2012) 1.12
A prospective PCR-based screening for the EML4-ALK oncogene in non-small cell lung cancer. Clin Cancer Res (2012) 1.12
Nrf2-deficiency creates a responsive microenvironment for metastasis to the lung. Carcinogenesis (2010) 1.12
Regulation of ADF/cofilin phosphorylation and synaptic function by LIM-kinase. Neuropharmacology (2004) 1.10